Polycythaemia vera and precision medicine: a prescription for the 21st century
Mené sur 173 patients atteints d'une maladie de Vaquez sans splénomégalie, cet essai de phase IIIb évalue l'efficacité, du point de vue du pourcentage de patients présentant un taux d'hématocrite stable en semaine 28, et la toxicité du ruxolitinib en traitement de seconde ligne
Polycythaemia vera is the most common myeloproliferative neoplasm and the ultimate phenotypic consequence of the Janus kinase 2 (JAK2) Val617Phe mutation. First described in the 19th century, we now understand the molecular pathogenesis of polycythaemia vera, its natural history, and the basis for its many complications. Remarkably, however, still no consensus exists about its clinical management.
The Lancet Oncology 2016